Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
5.71
-0.15 (-2.56%)
At close: Mar 28, 2025, 4:00 PM
5.36
-0.35 (-6.19%)
After-hours: Mar 28, 2025, 4:26 PM EDT
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Enanta Pharmaceuticals stock have an average target of 17.25, with a low estimate of 10 and a high estimate of 21. The average target predicts an increase of 202.10% from the current stock price of 5.71.
Analyst Consensus: Buy
* Price targets were last updated on Feb 11, 2025.
Analyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 0 | 0 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JMP Securities | JMP Securities | Buy Reiterates $21 | Buy | Reiterates | $21 | +267.78% | Feb 11, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +215.24% | Feb 11, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $18 | Strong Buy | Maintains | $27 → $18 | +215.24% | Dec 24, 2024 |
Baird | Baird | Buy Maintains $26 → $20 | Buy | Maintains | $26 → $20 | +250.26% | Nov 26, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $22 → $21 | Buy | Reiterates | $22 → $21 | +267.78% | Nov 26, 2024 |
Financial Forecast
Revenue This Year
64.04M
from 67.64M
Decreased by -5.31%
Revenue Next Year
56.21M
from 64.04M
Decreased by -12.23%
EPS This Year
-4.58
from -5.48
EPS Next Year
-5.28
from -4.58
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 70.9M | 73.6M | 70.7M | ||
Avg | 64.0M | 56.2M | 48.3M | ||
Low | 56.8M | 32.3M | 30.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 4.8% | 14.9% | 25.7% | ||
Avg | -5.3% | -12.2% | -14.0% | ||
Low | -16.0% | -49.5% | -46.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.11 | -2.61 | -1.84 | ||
Avg | -4.58 | -5.28 | -5.89 | ||
Low | -6.16 | -9.31 | -9.60 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.